Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Determinants of serum antipyrine half-lives in patients with liver disease

Determinants of serum antipyrine half-lives in patients with liver disease Antipyrine has been used as a model drug to investigate the effects of liver disease on drug metabolism in man. A prolongation in antipyrine half-life (T½) was found in patients with liver disease, patients with chronic liver disease showing a greater increase than those with acute, reversible pathology. The most marked prolongation in T½ was found in association with hypoalbuminaemia and hypoprothrombinaemia, suggesting that the cause for these changes was defective protein synthesis of microsomal enzyme protein. This hypothesis was supported by demonstrating that enzyme-inducing agents, which are known to increase the amount of microsomal enzyme protein, reduced the antipyrine half-life. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Gut British Medical Journal

Determinants of serum antipyrine half-lives in patients with liver disease

Branch, R. A.; Herbert, Carol M.; Read, Alan E.
Gut , Volume 14 (7) – Jul 1, 1973
Download PDF

Determinants of serum antipyrine half-lives in patients with liver disease

Branch, R. A.; Herbert, Carol M.; Read, Alan E.
Gut , Volume 14 (7) – Jul 1, 1973

Abstract


Antipyrine has been used as a model drug to investigate the effects of liver disease on drug metabolism in man. A prolongation in antipyrine half-life (T½) was found in patients with liver disease, patients with chronic liver disease showing a greater increase than those with acute, reversible pathology. The most marked prolongation in T½ was found in association with hypoalbuminaemia and hypoprothrombinaemia, suggesting that the cause for these changes was defective protein synthesis of microsomal enzyme protein. This hypothesis was supported by demonstrating that enzyme-inducing agents, which are known to increase the amount of microsomal enzyme protein, reduced the antipyrine half-life.

Loading next page...
 
/lp/british-medical-journal/determinants-of-serum-antipyrine-half-lives-in-patients-with-liver-doDD70cmuH

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
British Medical Journal
ISSN
0017-5749
eISSN
1468-3288
DOI
10.1136/gut.14.7.569
Publisher site
See Article on Publisher Site

Abstract

Antipyrine has been used as a model drug to investigate the effects of liver disease on drug metabolism in man. A prolongation in antipyrine half-life (T½) was found in patients with liver disease, patients with chronic liver disease showing a greater increase than those with acute, reversible pathology. The most marked prolongation in T½ was found in association with hypoalbuminaemia and hypoprothrombinaemia, suggesting that the cause for these changes was defective protein synthesis of microsomal enzyme protein. This hypothesis was supported by demonstrating that enzyme-inducing agents, which are known to increase the amount of microsomal enzyme protein, reduced the antipyrine half-life.

Journal

Gut – British Medical Journal

Published: Jul 1, 1973

References

  • Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease
    Acocella, G.; Bonollo, L.; Garimoldi, M.; Mainardi, M.; Tenconi, L.T.; Nicolis, F.B.
  • Influence of nitrazepam on oral anticoagulation with phenprocoumon
    Bieger, R.; de Jonge, H.; Loeliger, E.A.
  • The fate of antipyrine in man
    Brodie, B.B.; Axelrod, J.
  • The estimation of antipyrine in biological materials
    Brodie, B.B.; Axelrod, J.; Soberman, R.; Levy, B.B.
  • Metabolism ofdrugs in subjects with Laennec's cirrhosis